Home » Newsletters » BioWorld Science

BioWorld Science

March 19, 2008

View Archived Issues

Recent GSK patent reports novel treatment options for renal disorders

Preclinical, clinical studies describe activity, tolerability, pharmacokinetics of AMG-317

MEDI-563 mechanism, biological activity reported

Mometasone increases days with minimal symptoms in rhinosinusitis patients

Rapid symptom relief seen with icatibant in hereditary angioedema attacks

Archemix initiates phase II trial in thrombotic thrombocytopenic purpura

Millennium adds new IBD development candidate to its pipeline

Targacept initiates phase I trial of TC-5214 in major depressive disorder

Recent patents disclose new anticancer agents

Valeant reports encouraging phase IIb results at week 12 for taribavirin

Akesis provides preliminary data from AKP-020 phase IIa type 2 diabetes trial

Vasogen prepares response to FDA regarding ACCLAIM II clinical trial of Celacade

Ipsen submits BLA to the FDA for Reloxin in aesthetic indications

Merrimack completes enrollment in phase II trial of MM-093 in rheumatoid arthritis

BioCancell initiates treatment in phase IIb clinical trial of BC-819 for superficial bladder cancer

Astellas receives approvable letter for NDA for once-daily tacrolimus in kidney transplants

Novel beta-glucuronidase analogue shows promise in murine mucopolysaccharidosis VII

Nerve growth factor mimetic peptide effective in rat neuropathic pain model

Omrix receives FDA approval to initiate phase II clinical trial of fibrin patch product

FDA does not grant approval for Genta's Genasense in chronic lymphocytic leukemia

DSMB recommends continuation of Arena's phase III BLOOM trial of lorcaserin in obesity

Nisshin Kyorin receives approval for ulcerative colitis agent Pentasa

Milatuzumab receives FDA orphan drug designation for multiple myeloma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...